Study reveals how chemotherapy drugs boost immunotherapy response in hard-to-treat gastric cancer

Gastric cancer remains one of the world's deadliest malignancies, and doctors have learned that a class of drugs called immune checkpoint inhibitors can help some patients fight back. But there's a catch: these drugs work poorly in a subset of tumors with proficient mismatch repair systems—a genetic feature that makes cancer cells harder to recognize and attack. For years, researchers suspected that pairing immunotherapy with traditional chemotherapy might solve this problem, but nobody had mapped out exactly how it would work in gastric cancer cells. A new study published in Nature fills that gap, revealing a precise mechanism that could reshape how doctors treat this resistant form of the disease.

The research team focused on three drugs already in clinical use: two chemotherapy agents called 5-fluorouracil and cisplatin, and an anti-angiogenic drug called apatinib that starves tumors of blood supply. They tested these drugs on AGS gastric cancer cells—a standard laboratory model—that carried the proficient mismatch repair signature. The question was simple but crucial: could these drugs nudge cancer cells to display more PD-L1, a protein that immune checkpoint inhibitors are designed to target? The researchers used multiple techniques to measure what was happening at the molecular level. They watched cells die under drug treatment using standard viability assays. They measured messenger RNA levels with real-time PCR. They tracked protein changes with western blotting. Over 72 to 96 hours, all three drugs slowed cancer cell growth in a dose-dependent manner—the higher the concentration, the stronger the effect.

But the real discovery came when they looked at PD-L1 expression. At specific concentrations—5-fluorouracil at 64 micromolar, cisplatin at 16 micromolar, and apatinib at 320 and 640 nanomolar—the drugs significantly ramped up both PD-L1 messenger RNA and the actual protein itself. This was the opening the researchers were hunting for. If chemotherapy could force cancer cells to display more of the very target that immunotherapy drugs attack, combining the two approaches might work better than either alone.

The harder question was why. The team traced the mechanism through two major cellular signaling highways: the PI3K/Akt/mTOR pathway and the RAS/RAF/MEK/ERK pathway. Both are known to regulate PD-L1 expression, and both are disrupted in cancer. When they analyzed what each drug did to these pathways, the picture became more complex. All three drugs increased PI3K protein levels, but their downstream effects diverged. Apatinib boosted phosphorylated Akt—a key signaling molecule—while 5-fluorouracil and cisplatin actually suppressed it. Meanwhile, 5-fluorouracil ramped up MEK1 and ERK proteins, whereas apatinib and cisplatin turned them down. The drugs were hitting the same target through different routes, like three roads leading to the same destination.

What emerges from this work is a roadmap for combination therapy. The data suggest that adding traditional chemotherapy or anti-angiogenic drugs to immune checkpoint inhibitors could overcome the resistance that currently limits treatment in proficient mismatch repair gastric cancers. The mechanism is now visible: these drugs don't just kill cancer cells directly; they also reprogram those cells to become more visible to the immune system. For patients with this aggressive form of gastric cancer—a group that has historically had few good options—this finding opens a concrete path forward. The next step is clinical testing, where researchers will need to confirm that what works in laboratory dishes translates to real patients. But the theoretical foundation is now solid, and that changes what doctors can reasonably hope to attempt.